HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 3 (2006), Issue 12 (December)

1. The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay.
   Virol J, 3: 99. [Abstract] [Full-text]
2. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction.
   Obstet Gynecol, 108(6): 1423-31. [Abstract] [Full-text]
3. Effect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa: a cluster randomised trial.
   Lancet, 368(9551): 1973-83. [Abstract] [Full-text]
4. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection.
   Pediatrics, 118(6): e1745-57. [Abstract] [Full-text]
5. Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance.
   Bioinformatics, 22(24): 2975-9. [Abstract] [Full-text]
6. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
   Clin Infect Dis, 44(1): 141-4. [Abstract] [Full-text]
7. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?
   Clin Infect Dis, 44(1): 135-8. [Abstract] [Full-text]
8. HIV viral load monitoring in resource-limited regions: optional or necessary?
   Clin Infect Dis, 44(1): 128-34. [Abstract] [Full-text]
9. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
   Clin Infect Dis, 44(1): 120-7. [Abstract] [Full-text]
10. A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
    Clin Infect Dis, 44(1): 111-9. [Abstract] [Full-text]
11. Influence of human T cell lymphotropic virus type 2 coinfection on virological and immunological parameters in HIV type 1-infected patients.
    Clin Infect Dis, 44(1): 105-10. [Abstract] [Full-text]
12. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission.
    Clin Infect Dis, 44(1): 94-102. [Abstract] [Full-text]
13. Progression towards AIDS leads to increased Torque teno virus and Torque teno minivirus titers in tissues of HIV infected individuals.
    J Med Virol, 79(1): 1-7. [Abstract] [Full-text]
14. Human herpesvirus 8 genoprevalence in populations at disparate risks of Kaposi's sarcoma.
    J Med Virol, 79(1): 52-9. [Abstract] [Full-text]
15. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
    J Mol Biol, 365(1): 77-89. [Abstract] [Full-text]
16. Site-directed mutagenesis in the fingers subdomain of HIV-1 reverse transcriptase reveals a specific role for the beta3-beta4 hairpin loop in dNTP selection.
    J Mol Biol, 365(1): 38-49. [Abstract] [Full-text]
17. Structure-based mutagenesis of the integrase-LEDGF/p75 interface uncouples a strict correlation between in vitro protein binding and HIV-1 fitness.
    Virology, 357(1): 79-90. [Abstract] [Full-text]
18. HIV-1 negatively affects the survival/maturation of cord blood CD34(+) hematopoietic progenitor cells differentiated towards megakaryocytic lineage by HIV-1 gp120/CD4 membrane interaction.
    J Cell Physiol, 210(2): 315-24. [Abstract] [Full-text]
19. Direct impact of inactivated HIV-1 virions on B lymphocyte subsets.
    Mol Immunol, 44(8): 2124-34. [Abstract] [Full-text]
20. Montelukast in the treatment of HIV associated immune reconstitution disease.
    Sex Transm Infect, 82(6): 513-4. [Abstract] [Full-text]
21. Abacavir/lamividune combination in the treatment of HIV-1 infection: a review.
    Expert Opin Pharmacother, 7(18): 2571-80. [Abstract] [Full-text]
22. An economic commentary on the occurrence and control of HIV/AIDS in developing countries: special reference to India.
    Expert Opin Pharmacother, 7(18): 2447-54. [Abstract] [Full-text]
23. Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection.
    Sex Transm Infect, 82(6): 458-60. [Abstract] [Full-text]
24. Commercial sex venues: a closer look at their impact on the syphilis and HIV epidemics among men who have sex with men.
    Sex Transm Infect, 82(6): 439-43. [Abstract] [Full-text]
25. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa.
    Science, 314(5805): 1603-6. [Abstract] [Full-text]
26. Sexual and reproductive health for all: a call for action.
    Lancet, 368(9552): 2095-100. [Abstract] [Full-text]
27. Novel inhibitors of the early steps of the HIV-1 life cycle.
    Expert Opin Investig Drugs, 16(1): 11-23. [Abstract] [Full-text]
28. Hypothermia-induced J waves.
    Int J Cardiol, 114(3): e116-7. [Abstract] [Full-text]
29. Dissecting the protein-RNA and RNA-RNA interactions in the nucleocapsid-mediated dimerization and isomerization of HIV-1 stemloop 1.
    J Mol Biol, 365(2): 396-410. [Abstract] [Full-text]
30. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
    J Mol Biol, 365(2): 298-309. [Abstract] [Full-text]
31. Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance.
    Curr Med Res Opin, 22(12): 2603-12. [Abstract] [Full-text]
32. Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study.
    BMC Neurol, 6: 42. [Abstract] [Full-text]
33. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    Lancet, 368(9553): 2125-35. [Abstract] [Full-text]
34. Epidemiologic investigation of a cluster of workplace HIV infections in the adult film industry: Los Angeles, California, 2004.
    Clin Infect Dis, 44(2): 301-5. [Abstract] [Full-text]
35. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Clin Infect Dis, 44(2): 295-300. [Abstract] [Full-text]
36. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study.
    Clin Infect Dis, 44(2): 287-94. [Abstract] [Full-text]
37. Effects of high-intensity endurance and resistance exercise on HIV metabolic abnormalities: a pilot study.
    Biol Res Nurs, 8(3): 177-85. [Abstract] [Full-text]
38. An ultrasound-based comparative study on carotid plaques in HIV-positive patients vs. atherosclerotic and arteritis patients: atherosclerotic or inflammatory lesions?
    Coron Artery Dis, 18(1): 23-9. [Abstract] [Full-text]
39. Plasma adenosine deaminase activity among HIV1 Clade C seropositives: relation to CD4 T cell population and antiretroviral therapy.
    Clin Chim Acta, 377(1): 133-7. [Abstract] [Full-text]
40. Public image and governance of epidemics: comparing HIV/AIDS and SARS.
    Health Policy, 80(2): 253-72. [Abstract] [Full-text]
41. Diffusion tensor imaging with quantitative fibre tracking in HIV infection and alcoholism comorbidity: synergistic white matter damage.
    Brain, 130: 48-64. [Abstract] [Full-text]
42. Estimating incidence of HIV infection in childbearing age African women using serial prevalence data from antenatal clinics.
    Stat Med, 26(2): 320-35. [Abstract] [Full-text]
43. Analysis of interval-censored data from circular migrant and non-migrant sexual partnerships using the EM algorithm.
    Stat Med, 26(2): 309-19. [Abstract] [Full-text]
44. HIV in prison in low-income and middle-income countries.
    Lancet Infect Dis, 7(1): 32-41. [Abstract] [Full-text]
45. Synthesis and anti-human immunodeficiency virus activity of 4'-branched (+/-)-4'-thiostavudines.
    J Med Chem, 49(26): 7861-7. [Abstract] [Full-text]
46. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
    J Med Chem, 49(26): 7697-710. [Abstract] [Full-text]
47. Insights on resistance to reverse transcriptase: the different patterns of interaction of the nucleoside reverse transcriptase inhibitors in the deoxyribonucleotide triphosphate binding site relative to the normal substrate.
    J Med Chem, 49(26): 7675-82. [Abstract] [Full-text]
48. High levels of CXCL10 are produced by intestinal epithelial cells in AIDS patients with active cryptosporidiosis but not after reconstitution of immunity.
    Infect Immun, 75(1): 481-7. [Abstract] [Full-text]
49. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City.
    Am J Public Health, 97(1): 117-24. [Abstract] [Full-text]
50. Going beyond "ABC" to include "GEM": critical reflections on progress in the HIV/AIDS epidemic.
    Am J Public Health, 97(1): 13-8. [Abstract] [Full-text]
51. Sexual and drug behavior patterns and HIV and STD racial disparities: the need for new directions.
    Am J Public Health, 97(1): 125-32. [Abstract] [Full-text]
52. Best-evidence interventions: findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000-2004.
    Am J Public Health, 97(1): 133-43. [Abstract] [Full-text]
53. Characteristics of persons with heterosexually acquired HIV infection, United States 1999-2004.
    Am J Public Health, 97(1): 144-9. [Abstract] [Full-text]
54. Assessment of HIV testing of urban injection drug users: implications for expansion of HIV testing and prevention efforts.
    Am J Public Health, 97(1): 110-6. [Abstract] [Full-text]
55. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV+ youth.
    J Adolesc Health, 40(1): 96-8. [Abstract] [Full-text]
56. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes.
    Mol Pharmacol, 71(1): 3-11. [Abstract] [Full-text]
57. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    J Med Virol, 79(2): 127-37. [Abstract] [Full-text]
58. Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance.
    J Med Virol, 79(2): 118-26. [Abstract] [Full-text]
59. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
    J Med Virol, 79(2): 105-10. [Abstract] [Full-text]
60. Apoptosis-associated gene expression in HIV-infected patients in response to successful antiretroviral therapy.
    J Med Virol, 79(2): 111-7. [Abstract] [Full-text]
61. Interactions between HIV-1 Gag molecules in solution: an inositol phosphate-mediated switch.
    J Mol Biol, 365(3): 799-811. [Abstract] [Full-text]
62. Conformation of the HIV-1 Gag protein in solution.
    J Mol Biol, 365(3): 812-24. [Abstract] [Full-text]
63. Viral gene expression in HIV transgenic mice is activated by Mycobacterium tuberculosis and suppressed after antimycobacterial chemotherapy.
    J Infect Dis, 195(2): 246-54. [Abstract] [Full-text]
64. HIV-1 replication is stimulated by sodium stibogluconate, the therapeutic mainstay in the treatment of leishmaniasis.
    J Infect Dis, 195(2): 236-45. [Abstract] [Full-text]
65. Mortality in siblings of patients coinfected with HIV and hepatitis C virus.
    J Infect Dis, 195(2): 230-5. [Abstract] [Full-text]
66. HIV-1 disease progression in breast-feeding and formula-feeding mothers: a prospective 2-year comparison of T cell subsets, HIV-1 RNA levels, and mortality.
    J Infect Dis, 195(2): 220-9. [Abstract] [Full-text]
67. Nuclear import of the preintegration complex is blocked upon infection by human immunodeficiency virus type 1 in mouse cells.
    J Virol, 81(2): 677-88. [Abstract] [Full-text]
68. Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.
    J Virol, 81(2): 525-31. [Abstract] [Full-text]
69. Inefficient human immunodeficiency virus replication in mobile lymphocytes.
    J Virol, 81(2): 1000-12. [Abstract] [Full-text]
70. Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection.
    J Virol, 81(2): 599-612. [Abstract] [Full-text]
71. Viral interactions in human lymphoid tissue: Human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation.
    J Virol, 81(2): 708-17. [Abstract] [Full-text]
72. Prolonged adherence of human immunodeficiency virus-derived vector particles to hematopoietic target cells leads to secondary transduction in vitro and in vivo.
    J Virol, 81(2): 639-49. [Abstract] [Full-text]
73. Inhibition of human immunodeficiency virus envelope glycoprotein- mediated single cell lysis by low-molecular-weight antagonists of viral entry.
    J Virol, 81(2): 532-8. [Abstract] [Full-text]
74. Cancer rates after year 2000 significantly decrease in children with perinatal HIV infection: a study by the Italian Register for HIV Infection in Children.
    J Clin Oncol, 25(1): 97-101. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.